Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Grifols granted licence for new Flebogamma DIF variant

Grifols granted licence for new Flebogamma DIF variant

16th December 2010

Grifols has won approval to distribute a new formulation of its intravenous immunoglobulin solution Flebogamma DIF in Europe.

The European Medicines Agency has granted the company a licence to market Flebogamma DIF 100mg/ml, which features a ten percent concentration level.

This new version of the treatment, which has also been approved in the US, has been described by the manufacturer as adhering to high quality standards and safety margins, thanks to the use of a patented manufacturing process.

It is the second formulation of the product to be released in Europe, following the 2008 launch of the five percent concentration option Flebogamma DIF 50 mg/ml.

The company said: "It will gradually be made available in all European Union countries, enabling Grifols to better attend to the needs of European health professionals and patients."

In October 2010, Grifols published its financial results for the first nine months of 2010, during which it saw a 7.1 percent year-on-year increase in turnover.ADNFCR-8000103-ID-800295220-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.